GSK (GSK) 6-K Director/pdmr Shareholding

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION


Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of


the Securities Exchange Act of 1934

For period ending 15 May 2018

GlaxoSmithKline plc

(Name of registrant)


980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)


Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F


Form 20-F x     Form 40-F


--


Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.


Yes      No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Sale of Ordinary Shares.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.6967	65,000
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-05-15
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


	GlaxoSmithKline plc
	(Registrant)
Date: May 15, 2018
	By: VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GlaxoSmithKline plc